FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197584367> ?p ?o ?g. }

• W3197584367 endingPage "506" @default.
• W3197584367 startingPage "498" @default.
• W3197584367 abstract "<b><i>Background:</i></b> Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an increased risk for myelosuppression and severe infections. <b><i>Objectives:</i></b> We investigated in this retrospective study the effect of low-dose gemcitabine in pretreated advanced-stage CTCL and in blastic plasmacytoid dendritic cell neoplasia (BPDCN) regarding overall response (OR), progression-free survival (PFS), and AE. <b><i>Material and Methods:</i></b> A retrospective, multicenter study was conducted on 64 CTCL and BPDCN patients treated with gemcitabine in average absolute dosage of 1,800 mg/m² per cycle, which is 50% lower compared to standard dosage of 3,600 mg/m² per cycle (1,200 mg/m² day 1, 8, 15). Evaluation of response to therapy and AE was done 4–6 weeks after the sixth cycle. <b><i>Results:</i></b> OR was 62% with 11% demonstrating a complete response. The median time of PFS was 12 months and median time to next treatment was 7 months. Only 3/63 patients showed serious side effects, e.g., port infection or acute renal failure. Almost 73% of the patients experienced minor to moderate side effects (CTCAE grade 0–2). Fatigue (27.2%), fever (22.7%), and mild blood count alteration (18.2%) were the most common AE. <b><i>Conclusions:</i></b> This retrospective analysis supports the use of low-dose gemcitabine therapy in CTCL, demonstrating with 62% OR and PFS of 12 months an almost identical response rate and survival as compared to the standard dose therapy reported in previous studies but with a significantly improved safety profile and tolerability." @default.
• W3197584367 created "2021-09-13" @default.
• W3197584367 creator A5000675916 @default.
• W3197584367 creator A5006124541 @default.
• W3197584367 creator A5010722171 @default.
• W3197584367 creator A5014442576 @default.
• W3197584367 creator A5030298095 @default.
• W3197584367 creator A5033388734 @default.
• W3197584367 creator A5036812697 @default.
• W3197584367 creator A5043269673 @default.
• W3197584367 creator A5044054425 @default.
• W3197584367 creator A5050004807 @default.
• W3197584367 creator A5052915645 @default.
• W3197584367 creator A5052921309 @default.
• W3197584367 creator A5055279662 @default.
• W3197584367 date "2021-09-02" @default.
• W3197584367 modified "2023-10-01" @default.
• W3197584367 title "Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network" @default.
• W3197584367 cites W1545264161 @default.
• W3197584367 cites W1986043360 @default.
• W3197584367 cites W1986778063 @default.
• W3197584367 cites W2000940176 @default.
• W3197584367 cites W2020904611 @default.
• W3197584367 cites W2030646983 @default.
• W3197584367 cites W2032419702 @default.
• W3197584367 cites W2040390735 @default.
• W3197584367 cites W2055194877 @default.
• W3197584367 cites W2073100914 @default.
• W3197584367 cites W2081302558 @default.
• W3197584367 cites W2084959119 @default.
• W3197584367 cites W2124482385 @default.
• W3197584367 cites W2140608535 @default.
• W3197584367 cites W2601178524 @default.
• W3197584367 cites W2801119848 @default.
• W3197584367 cites W2909964376 @default.
• W3197584367 cites W2970899886 @default.
• W3197584367 cites W3048521621 @default.
• W3197584367 cites W3049212519 @default.
• W3197584367 cites W3131970728 @default.
• W3197584367 doi "https://doi.org/10.1159/000517830" @default.
• W3197584367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34474414" @default.
• W3197584367 hasPublicationYear "2021" @default.
• W3197584367 type Work @default.
• W3197584367 sameAs 3197584367 @default.
• W3197584367 citedByCount "5" @default.
• W3197584367 countsByYear W31975843672021 @default.
• W3197584367 countsByYear W31975843672022 @default.
• W3197584367 crossrefType "journal-article" @default.
• W3197584367 hasAuthorship W3197584367A5000675916 @default.
• W3197584367 hasAuthorship W3197584367A5006124541 @default.
• W3197584367 hasAuthorship W3197584367A5010722171 @default.
• W3197584367 hasAuthorship W3197584367A5014442576 @default.
• W3197584367 hasAuthorship W3197584367A5030298095 @default.
• W3197584367 hasAuthorship W3197584367A5033388734 @default.
• W3197584367 hasAuthorship W3197584367A5036812697 @default.
• W3197584367 hasAuthorship W3197584367A5043269673 @default.
• W3197584367 hasAuthorship W3197584367A5044054425 @default.
• W3197584367 hasAuthorship W3197584367A5050004807 @default.
• W3197584367 hasAuthorship W3197584367A5052915645 @default.
• W3197584367 hasAuthorship W3197584367A5052921309 @default.
• W3197584367 hasAuthorship W3197584367A5055279662 @default.
• W3197584367 hasConcept C126322002 @default.
• W3197584367 hasConcept C197934379 @default.
• W3197584367 hasConcept C2776694085 @default.
• W3197584367 hasConcept C2776780870 @default.
• W3197584367 hasConcept C2777756187 @default.
• W3197584367 hasConcept C2779338263 @default.
• W3197584367 hasConcept C2780073493 @default.
• W3197584367 hasConcept C2780258809 @default.
• W3197584367 hasConcept C2781413609 @default.
• W3197584367 hasConcept C71924100 @default.
• W3197584367 hasConcept C90924648 @default.
• W3197584367 hasConceptScore W3197584367C126322002 @default.
• W3197584367 hasConceptScore W3197584367C197934379 @default.
• W3197584367 hasConceptScore W3197584367C2776694085 @default.
• W3197584367 hasConceptScore W3197584367C2776780870 @default.
• W3197584367 hasConceptScore W3197584367C2777756187 @default.
• W3197584367 hasConceptScore W3197584367C2779338263 @default.
• W3197584367 hasConceptScore W3197584367C2780073493 @default.
• W3197584367 hasConceptScore W3197584367C2780258809 @default.
• W3197584367 hasConceptScore W3197584367C2781413609 @default.
• W3197584367 hasConceptScore W3197584367C71924100 @default.
• W3197584367 hasConceptScore W3197584367C90924648 @default.
• W3197584367 hasIssue "3" @default.
• W3197584367 hasLocation W31975843671 @default.
• W3197584367 hasLocation W31975843672 @default.
• W3197584367 hasOpenAccess W3197584367 @default.
• W3197584367 hasPrimaryLocation W31975843671 @default.
• W3197584367 hasRelatedWork W2030033571 @default.
• W3197584367 hasRelatedWork W2038483689 @default.
• W3197584367 hasRelatedWork W2040390735 @default.
• W3197584367 hasRelatedWork W2374795505 @default.
• W3197584367 hasRelatedWork W2377396290 @default.
• W3197584367 hasRelatedWork W2378715638 @default.
• W3197584367 hasRelatedWork W2406666758 @default.
• W3197584367 hasRelatedWork W2440918980 @default.
• W3197584367 hasRelatedWork W2978686655 @default.
• W3197584367 hasRelatedWork W3179705755 @default.

• next